Received Dec 2, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
Potential Arexvy additional doses; This non-serious case was reported by a pharmacist via sales rep and described the occurrence of extra dose administered in a patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis. On an unknown date, the patient received the 2nd dose of Arexvy. On an unknown date, an unknown time after receiving Arexvy, the patient experienced extra dose administered (Verbatim: Potential Arexvy additional doses). The outcome of the extra dose administered was not applicable. Additional Information: GSK Receipt Date: 21-NOV-2025 and 24-NOV-2025 The reporter had asked about the RSV (Arexvy) vaccine that if a patient had received a second RSV vaccine a few years after the initial dose, would there have been any potential issues. The reporter was aware that RSV vaccine was a single-dose product, but the patient had either forgotten or did not know they had already received one, and the pharmacy was unaware. No adverse event was mentioned. The batch number was not provided upon follow- up with the reporter.